Lynparza is the brand name for olaparib, a poly ADP-ribose polymerase (PARP) inhibitor used across multiple BRCA/HRR-associated cancers. Its indications include ovarian, fallopian tube, peritoneal, breast, pancreatic, and prostate cancers in specific biomarker-defined settings. The FDA first approved Lynparza on December 19, 2014.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
The FDA has granted fast track designation to ART6043 plus olaparib for germline BRCA-mutated HER2-negative breast cancer and to BriaCell's Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer, both addressing significant unmet medical needs.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04041128 |
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer |
COMPLETED | EARLY_PHASE1 |
